ATAGI/THANZ statement provides further guidance for the AstraZeneca vaccine and narrows contraindication

The Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) have released a joint statement on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of the COVID-19 Vaccine AstraZeneca.

Date published:
General public

The joint statement provides updated information about TTS and reaffirms ATAGI’s previous advice regarding the safe use of the AstraZeneca COVID-19 Vaccine.

It provides greater clarity on the nature of TTS and narrows the conditions determined to be contraindications for use of the vaccine.

The Chief Medical Officer (CMO) has also written to healthcare professionals regarding the joint statement.

Read the statement

Help us improve

If you would like a response please use the enquiries form instead.